Permanent URI for this collection
Browse
Recent Submissions
Publication Impact immediate treatment interruption of secukinumab efficacy in patients with active psoriatic arthritis and ankylosing spondylitis: interim analysis results from the SERENA study(Rheumatology, 2022) Gullick, Nicola; Gullick, Nicola; 11. Gaffney K, Kiltz U, Sfikakis P, Gullick N; Medical and DentalNot availablePublication Secukinumab retention and safety in patients with active psoriatic arthritis or ankylosing spondylitis: 2 year interim results of the observational SERENA study(Rheumatology, 2022) Gullick, Nicola; 10. Gaffney K, Kiltz U, Sfikakis P, Gullick N; Medical and DentalNot availablePublication Which Route and Dose of Corticosteroids Is Most Effective in Inducing Remission in Early Rheumatoid Arthritis?(Rheumatology, 2022) Gullick, Nicola; 6. Parker L, Gullick N; Medical and DentalNot availablePublication al Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis Arthritis(Rheumatology, 2022) Gullick, Nicola; Kiltz U, Sfikakis P, Gullick N; Medical and DentalNot AvailablePublication A 24-month prospective psoriatic arthritis observational study of persistence of treatment - interim analysis of baseline characteristics(Rheumatology, 2023) Gullick, Nicola; Joven-Ibanez B, Holzkaemper T, El Baou C, Unger E, Semeraro A, Gullick N, Treuer T; Medical and DentalNot AvailablePublication AB1115 Study design and full baseline sample characteristics of patients from the 24 month multinational perspective psoriatic arthritis observation study of persistence of treatment (PRO-SPIRIT)(BMJ Publishing Group, 2023) Gullick, Nicola; University Hospitals Coventry and Warwickshire NHS Trust; Gullick, Nicolano abstract acvailablePublication Analgesic efficacy of therapies used for complex regional pain syndrome: a systematic review(BMJ Publishing Group, 2023) Gullick, Nicola; Shekarsarai C, Gullick N; Medical and DentalAnalgesic efficacy of therapies used for complex regional pain syndrome: a systematic reviewPublication Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel of healthcare professionals in the UK(BMJ Publishing Group, 2023) Gullick, Nicola; Coates LC, Bukhari M, Chan A, Choy E, Galloway J, Gullick N, et al; Medical and DentalEnhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel of healthcare professionals in the UKPublication Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.(Elsevier, 2022-06-27) Abhishek, Abhishek; Boyton, Rosemary J; Peckham, Nicholas; McKnight, Áine; Coates, Laura C; Bluett, James; Barber, Vicki; Cureton, Lucy; Francis, Anne; Appelbe, Duncan; Eldridge, Lucy; Julier, Patrick; Valdes, Ana M; Brooks, Tim; Rombach, Ines; Altmann, Daniel M; Nguyen-Van-Tam, Jonathan S; Williams, Hywel C; Cook, Jonathan A; 9. Abhishek A, Boyton RJ, Peckham N, McKnight Á, Coates LC, Bluett J, et al; Medical and Dentalno AbstractPublication Relapse after cessation of weekly tocilizumab for giant cell arteritis : a multicentre service evaluation in England(OUP, 2023-11-11) Alkoky, Hoda; Bukhari, Marwan; Carter, Stuart; Coath, Fiona L; Davidson, Brian; Doddamani, Parveen; Dubey, Shirish; Ducker, Georgina; Griffiths, Bridget; Heaney, Jonathan; Holloway, Amelia; Htut, Ei Ei Phyu; Hughes, Mark; Irvine, Hannah; Kinder, Alison; Kurshid, Asim; Lim, Joyce; Ludwig, Dalia R; Malik, Mariam; Mercer, Louise; Mulhearn, Ben; Nair, Jagdish R; Patel, Rikesh; Robson, Joanna; Saha, Pratyasha; Tansley, Sarah; Mackie, Sarah L; 1. Quick V, Abusalameh M, Ahmed S, et al; Medical and DentalNo AbstractPublication Immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies (Protocol - Intervention) Cochrane Database of Systematic Reviews(Cochrane Database of Systematic Reviews, 2023) Gullick, Nicola; Raaphorst J, Gullick NJ, Pipitone N, Shokraneh F, Brassington R, Ali SS, Gordon PANo AbstractPublication The protocol of a clinical effectiveness trial comparing standard step up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomised controlled trial(Sage Publications, 2023-10) Gullick, Nicola; Watson M, Tillett W, Jadon D, Massa S, Francis A, Gullick N, et al; Medical and DentalNo AbstractPublication A first in disease phase 2a randomised, controlled trial of Granulocyte-Macrophage Colony-Stimulating factor neutralisation for Axial Spondyloarthritis (NAMASTE study)(Elsevier, 2023-08) Gullick, Nicola; • Worth C, Al-Mossawi MH, Macdonald J, Fisher B, Chan A, Sengupta R et al.; Medical and DentalNo AbstractPublication Obesity in Rheumatoid Arthritis: impact on response to biologic therapies(Exploration of Musculoskeletal Diseases, 2023-12-15) Gullick, Nicola; • Irshad Z, Gullick N; Medical and DentalNo AbstractPublication More than skin-deep: visceral fat is strongly associated with disease activity, function and metabolic indices in psoriatic disease.(BMC, 2023-06-23) Gullick, Nicola J; Gullick, Nicola; Gullick, Nicola; Medical and Dental; Gullick, NicolaObjective: To compare body composition between patients with psoriatic disease (PsD), including cutaneous psoriasis (PsO) and psoriatic arthritis (PsA), and controls, and to explore associations between disease activity and measures of function and metabolic derangement.Publication Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis : interim 2-year analysis from SERENA(Oxford University Press, 2023-08-21) Gullick, Nicola; University Hospitals Coventry and Warwickshire NHS Trust; Medical and Dental; Gulllick, NicolaThe safety set comprised 189 patients (PsA, n = 81; r-axSpA, n = 108), and the target population set comprised 183 patients (PsA, n = 78; r-axSpA, n = 105). In the safety set, 107 patients (45 of 81 with PsA and 62 of 108 with r-axSpA) had previously received a biologic agent. Retention rates were similar between patients with PsA and r-axSpA after 1 year (PsA 91.0%, 95% CI: 84.0, 98.0; r-axSpA 89.2%, 95% CI: 82.7, 95.7) and 2 years (PsA 77.6%, 95% CI: 67.6, 87.7; r-axSpA 76.2%, 95% CI: 67.4, 85.0) of observation. Overall, 17.5% of patients (33 of 189) experienced at least one treatment-related adverse event, and 12.7% of patients (24 of 189) discontinued secukinumab because of adverse events.Publication Rheumatology patients on immunosuppressive treatment and their perioperative management: Review of recommendations.(Wiley, 2022-12-03) Khader, Shafeeqa Gulam; Hussain, Wajith Hussain Zahir; Moorthy, Arumugam; Medicine; Medical and Dental; Khader, Shafeeqa GulamNo abstract availablePublication Points to consider: EULAR-UEMS standards for the training of European rheumatologists.(BMJ Publishing Group, 2023-05-15) Alunno, Alessia; Avcin, Tadej; Haines, Catherine; Ramiro, Sofia; Sivera, Francisca; Badreh, Sara; Baraliakos, Xenofon; Bijlsma, Johannes W J; Buttgereit, Frank; Da Silva, Jose A P; Dudler, Jean; Ferreira, Ricardo J O; Gudu, Tania; Hachulla, Eric; Holland-Fischer, Mette; Iagnocco, Annamaria; Kragstrup, Tue Wenzel; Nagy, György; Romão, Vasco C; Stones, Simon R; van Onna, Marloes; Edwards, Christopher J; Chaudhuri, Kaushik; Medical; Medical and Dental; Chaudhuri, KaushikBackground: Postgraduate rheumatology training programmes are already established at a national level in most European countries. However, previous work has highlighted a substantial level of heterogeneity in the organisation and, in part, content of programmes. Objective: To define competences and standards of knowledge, skills and professional behaviours required for the training of rheumatologists.